While meta‐regression identified insulin as a comparator explaining 55% of between‐study variance, the residual heterogeneity likely reflects unmeasured confounding from differences in follow‐up duration, baseline liver disease severity, geographic variation, and healthcare systems. The gene discussed is INS; the disease is liver disorder.